1-3 of 3
Karolin Hubert, Mrs
Close
Sort by
Journal Articles

The Prognostic Impact of the Mutational Profile in Patients with Myelofibrosis in the Era of the JAK1/JAK2-Inhibitor Ruxolitinib

Haifa Kathrin Al-Ali, MD, Song-Yau Wang, Nadja Jaekel, MD, Anne Koehler, MD, Rainer Krahl, PhD, Karolin Hubert, Mrs, Thoralf Lange, MD, Martin Roskos, PhD, Rayak Stengel, PhD, Ines Kovacs, Mrs, Schwabe Scarlett, Mrs, Karoline Schubert, Kathrin Wildenberger, Melanie Schneider, Mrs, Elisabeth Koehler, Mrs, Dietger Niederwieser, MD
Journal: Blood
Blood (2014) 124 (21): 1860.
https://doi.org/10.1182/blood.V124.21.1860.1860
Published: 2014
Journal Articles

Complete Clinical, Histopathologic and Molecular Remission of Primary Myelofibrosis with Long-Term Treatment with the JAK1/2 Inhibitor Ruxolitinib

Haifa Kathrin Al-Ali, MD, Karolin Hubert, Mrs, Thoralf Lange, MD, Udo Siebolts, Claudia Wichenhauser, MD, Gopalakrishna Prashanth, MD MRCS, Dietger Niederwieser, MD, Astrid Monecke, MD
Journal: Blood
Blood (2014) 124 (21): 1836.
https://doi.org/10.1182/blood.V124.21.1836.1836
Published: 2014
Journal Articles

Efficacy and Safety of Deferasirox in Patients with Transfusional Iron Overload After Allogeneic Hematopoietic Cell Transplantation: The CICL670ADE02 Trial

Haifa Kathrin Al-Ali, MD, Nadja Jaekel, MD, Kai Lieder, Dr., Stefan Albrecht, PhD, Oliver Leismann, PhD, Karolin Hubert, Mrs, Gesine Bug, Nicolaus Kroeger, MD, Uwe Platzbecker, MD, Michael Stadler, MD, Katherina de Haas, MD, Dietger Niederwieser
Journal: Blood
Blood (2012) 120 (21): 485.
https://doi.org/10.1182/blood.V120.21.485.485
Published: 2012